• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Osteopenia and osteoporosis among treatment-experienced people living with HIV.治疗后艾滋病毒感染者的骨质疏松症和骨量减少症。
Braz J Infect Dis. 2020 Jul-Aug;24(4):288-295. doi: 10.1016/j.bjid.2020.05.008. Epub 2020 Jun 15.
2
Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.人类免疫缺陷病毒感染个体的骨密度降低:患病率及其危险因素的荟萃分析。
Osteoporos Int. 2018 Mar;29(3):595-613. doi: 10.1007/s00198-017-4305-8. Epub 2017 Nov 20.
3
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.HIV感染男性的骨质减少:与无症状性乳酸血症及抗逆转录病毒治疗前体重较低相关。
AIDS. 2001 Apr 13;15(6):703-9. doi: 10.1097/00002030-200104130-00005.
4
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.HIV感染患者的骨矿物质密度降低:患病率及相关因素。
AIDS. 2008 Jan 30;22(3):395-402. doi: 10.1097/QAD.0b013e3282f423dd.
5
[Factors associated with osteopenia and osteoporosis in women undergoing bone mineral density test].[接受骨密度检测的女性中与骨质减少和骨质疏松相关的因素]
Rev Bras Reumatol. 2015 May-Jun;55(3):223-8. doi: 10.1016/j.rbr.2014.08.012. Epub 2014 Oct 24.
6
Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.开始使用含替诺福韦方案的 HIV 感染者的骨密度变化:一项为期五年的前瞻性研究。
PLoS One. 2020 Mar 25;15(3):e0230368. doi: 10.1371/journal.pone.0230368. eCollection 2020.
7
Reduced bone mineral density among HIV-infected, virologically controlled young men: prevalence and associated factors.HIV 感染、病毒学控制的年轻男性中降低的骨矿物质密度:患病率及相关因素。
AIDS. 2018 Nov 28;32(18):2689-2696. doi: 10.1097/QAD.0000000000002001.
8
Risk Factors Associated with Osteopenia/Osteoporosis in Antiretroviral Therapy Naive HIV Patients.抗逆转录病毒治疗初治 HIV 患者的骨质疏松症/低骨量相关危险因素。
Curr HIV Res. 2024;22(4):259-265. doi: 10.2174/011570162X311238240603042806.
9
Timely care linkage of people living with HIV in a reference health service, Belo Horizonte, Minas Gerais.米纳斯吉拉斯州贝洛奥里藏特市一家参考医疗服务机构中艾滋病毒感染者的及时护理联系。
Rev Bras Epidemiol. 2020 Mar 9;23:e200020. doi: 10.1590/1980-549720200020. eCollection 2020.
10
Prevalence and risk factors for osteopenia/osteoporosis in an HIV-infected male population.HIV 感染男性人群中骨量减少/骨质疏松症的患病率和危险因素。
Wien Klin Wochenschr. 2007;119(21-22):639-46. doi: 10.1007/s00508-007-0844-x.

引用本文的文献

1
A multivariate analysis of the impact of HIV infection on the risk of osteoporosis based on the NHANES database.基于美国国家健康与营养检查调查(NHANES)数据库对HIV感染对骨质疏松风险影响的多变量分析。
Medicine (Baltimore). 2025 Sep 5;104(36):e44459. doi: 10.1097/MD.0000000000044459.
2
Evaluation of bone mineral density and its influencing factors in patients infected with HIV under antiretroviral therapy.接受抗逆转录病毒治疗的HIV感染患者的骨矿物质密度及其影响因素评估。
BMC Infect Dis. 2025 Jan 7;25(1):33. doi: 10.1186/s12879-024-10388-y.
3
Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV.评价 HIV 感染者换用多替拉韦利匹韦林双药治疗的疗效。
Afr Health Sci. 2022 Sep;22(3):426-435. doi: 10.4314/ahs.v22i3.46.
4
HIV and Substance Use in Latin America: A Scoping Review.HIV 与拉丁美洲的物质使用:范围综述。
Int J Environ Res Public Health. 2022 Jun 12;19(12):7198. doi: 10.3390/ijerph19127198.
5
Low bone mass and vitamin D in Brazilian people living with HIV under antiretroviral therapy.巴西接受抗逆转录病毒治疗的艾滋病毒感染者存在低骨量和维生素 D 缺乏。
Arch Osteoporos. 2022 Mar 5;17(1):40. doi: 10.1007/s11657-022-01088-8.

本文引用的文献

1
Low bone mineral density among HIV-infected patients in Brazil.巴西HIV感染患者的低骨矿物质密度。
Rev Inst Med Trop Sao Paulo. 2017 Dec 21;59:e89. doi: 10.1590/S1678-9946201759089.
2
Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.人类免疫缺陷病毒感染个体的骨密度降低:患病率及其危险因素的荟萃分析。
Osteoporos Int. 2018 Mar;29(3):595-613. doi: 10.1007/s00198-017-4305-8. Epub 2017 Nov 20.
3
Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: A cross-sectional study in Gansu province, Northwestern of China.绝经后女性和老年男性骨质疏松症的患病率及相关生活方式和代谢因素:中国西北部甘肃省的一项横断面研究。
Medicine (Baltimore). 2017 Oct;96(43):e8294. doi: 10.1097/MD.0000000000008294.
4
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.全球、区域和国家艾滋病毒发病率、流行率和死亡率估计数,1980-2015 年:2015 年全球疾病负担研究。
Lancet HIV. 2016 Aug;3(8):e361-e387. doi: 10.1016/S2352-3018(16)30087-X. Epub 2016 Jul 19.
5
Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected Adults.当代感染艾滋病毒的成年人群体中的衰弱和衰弱前期情况
J Frailty Aging. 2014;3(3):158-65. doi: 10.14283/jfa.2014.18.
6
The protease inhibitors and HIV-associated bone loss.蛋白酶抑制剂与HIV相关的骨质流失。
Curr Opin HIV AIDS. 2016 May;11(3):333-42. doi: 10.1097/COH.0000000000000260.
7
Tenofovir and bone health.替诺福韦与骨骼健康。
Curr Opin HIV AIDS. 2016 May;11(3):326-32. doi: 10.1097/COH.0000000000000248.
8
Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss.T细胞重建在HIV-1抗逆转录病毒疗法引起的骨质流失中的作用。
Nat Commun. 2015 Sep 22;6:8282. doi: 10.1038/ncomms9282.
9
High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy.现代抗逆转录病毒治疗时代,HIV感染者中低骨矿物质密度患病率高且4年内骨质大量流失
AIDS Res Hum Retroviruses. 2016 Jan;32(1):59-67. doi: 10.1089/aid.2015.0158. Epub 2015 Sep 14.
10
Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.维生素D和钙可减轻开始抗逆转录病毒治疗时的骨质流失:一项随机试验。
Ann Intern Med. 2015 Jun 16;162(12):815-24. doi: 10.7326/M14-1409.

治疗后艾滋病毒感染者的骨质疏松症和骨量减少症。

Osteopenia and osteoporosis among treatment-experienced people living with HIV.

机构信息

Universidade Federal de São João del-Rei, Divinópolis, MG, Brazil.

Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

出版信息

Braz J Infect Dis. 2020 Jul-Aug;24(4):288-295. doi: 10.1016/j.bjid.2020.05.008. Epub 2020 Jun 15.

DOI:10.1016/j.bjid.2020.05.008
PMID:32553468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9392122/
Abstract

INTRODUCTION

Life expectancy of people living with human immunodeficiency (PLHIV) has increased mainly due to the accessibility and effectiveness of antiretroviral therapy (ART). However, adverse effects from long-term use of antiretrovirals, and the physiological changes associated with aging, may compromise the quality of life of PLHIV, in addition to causing new demands on the healthcare system.

OBJECTIVES

Estimate the frequency of osteoporosis and osteopenia in patients on prolonged ART and to verify their associated factors.

METHODS

A cross-sectional study was conducted in Belo Horizonte, Minas Gerais, Brazil, from August 2017 to June 2018, in a sample of PLHIV (age ≥ 18 years) who started ART between 2001 and 2005. Data were collected through face-to-face interviews, physical evaluation, laboratory tests, and Dual-Energy X-Ray Absorptiometry Screening (DEXA). The outcome of interest was presence of bone alteration, defined as presence of osteopenia or osteoporosis in DEXA. The association between the explanatory variables and the event was assessed through odds ratio (OR) estimate, with 95% confidence interval (CI). Multiple logistic regression was performed to evaluate factors independently associated with bone alteration.

RESULTS

Among 92 participants, 47.8% presented bone alteration (19.6% osteoporosis and 28.2% osteopenia). The variables that remained in the final logistic regression model were age ≥ 50 years (OR: 12.53; 95% CI: 4.37-35.90) and current alcohol use (OR: 2.63; 95% CI: 0.94-7.37).

CONCLUSIONS

This study showed a high frequency of bone changes, especially in PLHIV older than 50 years. This information is useful to stimulate the screening and timely intervention of this comorbidity of PLHIV on prolonged use of ART in order to prevent or minimize complications and new demands on the healthcare system.

摘要

简介

由于抗逆转录病毒疗法(ART)的可及性和有效性,艾滋病毒感染者(PLHIV)的预期寿命有所延长。然而,长期使用抗逆转录病毒药物的副作用,以及与衰老相关的生理变化,可能会损害 PLHIV 的生活质量,此外还会给医疗保健系统带来新的需求。

目的

评估长期接受抗逆转录病毒治疗的患者中骨质疏松症和骨量减少症的发生率,并确定其相关因素。

方法

这是一项在巴西米纳斯吉拉斯州贝洛奥里藏特市进行的横断面研究,于 2017 年 8 月至 2018 年 6 月期间,对 2001 年至 2005 年间开始接受抗逆转录病毒治疗的 PLHIV(年龄≥18 岁)进行了抽样调查。通过面对面访谈、身体评估、实验室检查和双能 X 射线吸收法(DEXA)筛查收集数据。感兴趣的结局是骨骼改变的存在,定义为 DEXA 显示存在骨质疏松症或骨量减少症。通过比值比(OR)估计和 95%置信区间(CI)评估解释变量与事件之间的关联。进行多因素逻辑回归分析,以评估与骨骼改变独立相关的因素。

结果

在 92 名参与者中,47.8%的人存在骨骼改变(19.6%骨质疏松症和 28.2%骨量减少症)。最终逻辑回归模型中保留的变量为年龄≥50 岁(OR:12.53;95%CI:4.37-35.90)和当前饮酒(OR:2.63;95%CI:0.94-7.37)。

结论

本研究显示,骨改变的发生率较高,尤其是年龄大于 50 岁的 PLHIV。这些信息有助于促使对长期接受 ART 治疗的 PLHIV 进行这种合并症的筛查和及时干预,以预防或最小化并发症的发生,并减轻对医疗保健系统的新需求。